Neuromed Pharmaceuticals Ltd.
Industry
- Biotechnology
- Pharmaceuticals
Latest on Neuromed Pharmaceuticals Ltd.
They only come out towards the end of an IPO window. After investors have snapped up all the preclinical or Phase I-stage drug development companies and the venture capitalists are scratching around t
It's on to plan B for Zalicus, which saw its stock price drop 43.2% to $0.79 per share on 10 September after the company announced that it is dropping development of its lead drug candidate, Synavive,
CombinatoRx has reported a fourth quarter profit of $25.2 million on lower R&D spending and gains from its acquisition of Neuromed Pharmaceuticals. The US firm's shares closed up by 8% to $1.36 yester
CombinatoRx and privately held Neuromed Pharmaceuticals announced yesterday that they have closed their $28.8 million all-stock merger. CombinatoRx issued approximately 14.9 million new shares to Neur